Abstract

ObjectiveThe poor compliance to treatmentof Helicobacter pylori-infected patients is well-known. We evaluated the efficacy of daily single-dose triple therapy as compared to conventional triple therapyon patient compliance and eradication of H. pylori infection.MethodsIn the study group, 105 patients received esomeprazole 40mg, tinidazole 1g, and levofloxacin 500mg once-daily for 14days. One hundred and seven patients in the control group received lansoprazole 30mg, amoxicillin 1g, and clarithromycin 500mg twice-daily for 14days. Four weeks after completing therapy, urea breath test was performed to assess the eradication of H. pylori infection.ResultsThe eradication rates by intention-to-treat analysis were 86 and 90.2 and by per-protocol analyses were 90.5 and 95.3 in the control and study groups, respectively, with no significant differences. Drug compliance was significantly better in the study group compared to the control group (p=0.04). Overall, 44.7 of the patients in the study and 47.6 in the control groups had at least one adverse event. The most common adverse event was the dysgeusia in both thegroups. The occurrence of diarrhea, nausea and vomiting was significantly higher in the control group and that of arthralgia was higher in the study group. The presence of periodontal disease and drug compliance was independently associated with treatment failure.ConclusionThe use of single-dose PPI-based triple therapy improves drug compliance and eradication rate to standard PPI-based triple therapy. Presence of periodontal disease and drug compliance had negative influence on the eradication rate.